<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Immunother Cancer</journal-id><journal-id journal-id-type="iso-abbrev">J Immunother Cancer</journal-id><journal-title-group><journal-title>Journal for Immunotherapy of Cancer</journal-title></journal-title-group><issn pub-type="epub">2051-1426</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4645503</article-id><article-id pub-id-type="publisher-id">2051-1426-3-S2-P155</article-id><article-id pub-id-type="doi">10.1186/2051-1426-3-S2-P155</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Randomized Phase II study of the safety, efficacy and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR)</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Le</surname><given-names>Dung T</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Crocenzi</surname><given-names>Todd S</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Urum</surname><given-names>Jennifer N</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Lutz</surname><given-names>Eric R</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Laheru</surname><given-names>Daniel A</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Sugar</surname><given-names>Elizabeth A</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Vonderheide</surname><given-names>Robert H</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Fisher</surname><given-names>George A</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Ko</surname><given-names>Andrew H</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Murphy</surname><given-names>Aimee L</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>McDougall</surname><given-names>Katherine</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Ferber</surname><given-names>Sandy</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Brockstedt</surname><given-names>Dirk G</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Jaffee</surname><given-names>Elizabeth M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib></contrib-group><aff id="I1"><label>1</label>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA</aff><aff id="I2"><label>2</label>Providence Cancer Center, Portland, OR, USA</aff><aff id="I3"><label>3</label>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA</aff><aff id="I4"><label>4</label>Departments of Biostatistics and Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA</aff><aff id="I5"><label>5</label>University of Pennsylvania, Baltimore, MD, USA</aff><aff id="I6"><label>6</label>Stanford University School of Medicine, Stanford, CA, USA</aff><aff id="I7"><label>7</label>UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA</aff><aff id="I8"><label>8</label>Aduro BioTech, Inc., Berkeley, CA, USA</aff><aff id="I9"><label>9</label>Aduro Biotech, Berkeley, CA, USA</aff><aff id="I10"><label>10</label>Array Biostatistics LLC, Evanston, IL, USA</aff><aff id="I11"><label>11</label>Aduro Biotech, Inc., Berkeley, CA, USA</aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>4</day><month>11</month><year>2015</year></pub-date><volume>3</volume><issue>Suppl 2</issue><supplement><named-content content-type="supplement-title">30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was funded by SITC 2015.</named-content></supplement><fpage>P155</fpage><lpage>P155</lpage><permissions><copyright-statement>Copyright &#x000a9; 2015 Le et al.</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Le et al.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><self-uri xlink:href="http://www.immunotherapyofcancer.org/content/3/S2/P155"/><conference><conf-date>4-8 November 2015</conf-date><conf-name>30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)</conf-name><conf-loc>National Harbor, MD, USA</conf-loc></conference></article-meta></front><body><sec><title>Background</title><p>A heterologous prime-boost vaccination strategy using GVAX pancreas vaccine and CRS-207 is showing promise in patients with pancreatic adenocarcinoma (PDA) (Le, JCO 2015). Furthermore, blockade of the immune checkpoint programmed death-1 (PD-1) is active in some cancers. Combinatorial strategies aimed at priming tumor antigen-specific T cells while simultaneously blocking negative checkpoints may be necessary to improve outcomes in PDA. GVAX is composed of allogeneic pancreatic cancer cells modified to express GM-CSF and induces a broad response against multiple tumor antigens. GVAX is given with low-dose cyclophosphamide (CY) to inhibit regulatory T cells. CRS-207 is live-attenuated <italic>Listeria monocytogenes</italic> engineered to express the tumor-associated antigen mesothelin. CRS-207 boosts responses against mesothelin and is unique in its capacity to stimulate both innate and adaptive immunity by activating T cells and NK cells. Nivolumab is an antibody against PD-1.</p></sec><sec><title>Methods</title><p>This is a Phase II study comparing CY/GVAX and CRS-207 with or without nivolumab in subjects with PDA who failed only one chemotherapy regimen for metastatic disease. Subjects are randomized in a 1:1 ratio to receive either 2 doses of CY/nivolumab/GVAX and 4 doses of nivolumab/CRS-207 (Arm A) or 2 doses of CY/GVAX and 4 doses of CRS-207 (Arm B). The primary objective is to compare OS between Arms A and B. Secondary/exploratory objectives include: assessment of safety and clinical responses (tumor assessments and CA19-9 levels) and correlation of <italic>Lm</italic>- and mesothelin-specific T cell and other immunological responses with OS, progression-free survival and best overall response.</p></sec></body></article>